IMMUPHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.05 GBX | -0.49% |
|
-4.65% | +22.98% |
| Jun. 05 | EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows | AN |
| Jun. 05 | ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 16.39 | 26.78 | 33.4 | 16.51 | 6.135 | 6.942 |
| Enterprise Value (EV) 1 | 11.6 | 25.44 | 28.18 | 14.87 | 5.467 | 6.734 |
| P/E ratio | -2.26 x | -4.01 x | -3.89 x | -2.03 x | -1.46 x | -2.06 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 202 x | 344 x | 264 x | 140 x | - | - |
| EV / Revenue | 143 x | 326 x | 223 x | 126 x | - | - |
| EV / EBITDA | -1.46 x | -4.11 x | -5.2 x | -2.95 x | -1.88 x | -2.23 x |
| EV / FCF | -4.22 x | -7.29 x | -19 x | -8.31 x | -2.99 x | -6.82 x |
| FCF Yield | -23.7% | -13.7% | -5.26% | -12% | -33.5% | -14.7% |
| Price to Book | 2.15 x | 5.08 x | 3.46 x | 4.26 x | 2.43 x | 6.57 x |
| Nbr of stocks (in thousands) | 139,467 | 167,361 | 250,221 | 250,221 | 333,403 | 416,437 |
| Reference price 2 | 0.1175 | 0.1600 | 0.1335 | 0.0660 | 0.0184 | 0.0167 |
| Announcement Date | 6/3/19 | 4/30/20 | 4/29/21 | 5/24/22 | 6/6/23 | 6/5/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0813 | 0.0779 | 0.1267 | 0.1184 | - | - |
| EBITDA 1 | -7.947 | -6.194 | -5.418 | -5.046 | -2.911 | -3.025 |
| EBIT 1 | -8.08 | -6.282 | -5.589 | -5.16 | -3.029 | -3.063 |
| Operating Margin | -9,941.04% | -8,061.14% | -4,412.7% | -4,359.84% | - | - |
| Earnings before Tax (EBT) 1 | -7.955 | -6.744 | -7.246 | -8.941 | -4.456 | -3.419 |
| Net income 1 | -7.207 | -6.124 | -6.86 | -8.174 | -3.807 | -2.922 |
| Net margin | -8,866.22% | -7,858.31% | -5,415.72% | -6,906.55% | - | - |
| EPS 2 | -0.0519 | -0.0399 | -0.0343 | -0.0325 | -0.0126 | -0.008100 |
| Free Cash Flow 1 | -2.747 | -3.491 | -1.483 | -1.79 | -1.83 | -0.9874 |
| FCF margin | -3,379.38% | -4,479.68% | -1,171.12% | -1,512.14% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/3/19 | 4/30/20 | 4/29/21 | 5/24/22 | 6/6/23 | 6/5/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 4.79 | 1.34 | 5.22 | 1.65 | 0.67 | 0.21 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.75 | -3.49 | -1.48 | -1.79 | -1.83 | -0.99 |
| ROE (net income / shareholders' equity) | -129% | -95% | -91.9% | -116% | -110% | -163% |
| ROA (Net income/ Total Assets) | -73.9% | -54.3% | -41.8% | -38.1% | -38% | -57.2% |
| Assets 1 | 9.757 | 11.28 | 16.41 | 21.43 | 10.03 | 5.11 |
| Book Value Per Share 2 | 0.0500 | 0.0300 | 0.0400 | 0.0200 | 0.0100 | 0 |
| Cash Flow per Share 2 | 0.0400 | 0.0100 | 0.0200 | 0.0100 | 0 | 0 |
| Capex 1 | 0.1 | 0.11 | 0.36 | 0.05 | 0.11 | - |
| Capex / Sales | 126.57% | 137.45% | 284.44% | 43.04% | - | - |
| Announcement Date | 6/3/19 | 4/30/20 | 4/29/21 | 5/24/22 | 6/6/23 | 6/5/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +22.98% | 11.09M | |
| +22.10% | 46.55B | |
| +46.45% | 41.84B | |
| -3.12% | 40.84B | |
| +36.10% | 32.95B | |
| -6.30% | 28.27B | |
| +18.71% | 27.78B | |
| +46.15% | 14.26B | |
| +44.52% | 13.69B | |
| +0.19% | 12.18B |
- Stock Market
- Equities
- IMM Stock
- Financials ImmuPharma plc
